Motavizumab - New Biological Therapy for RSV Prevention
Key Data:
Drug (brand/generic)
Motavizumab
Company/Licensee
MedImmune (Part of AstraZeneca)
Therapy Class
Therapeutic MAb
Product Description
Recombinant humanised anti-RSV MAb
Current Indication
RSV Prevention
Market Sector
Anti-infectives
Development Status
Pre-registration US
